Insulin-like growth factor-l (IGF-I) is abundant in the circulation and has been shown to have a wide array of biologic effects. The authors carried out a cross-sectional community-based study of 420 men and 419 nonestrogen-using postmenopausal women aged 50-97 years to ascertain the within-person and laboratory reliability of IGF-I measurements, and the association of IGF-I with common epidemiologic confounders. There was no evidence of seasonal or diurnal variation. IGF-I decreased linearly with age in both sexes, with significantly lower levels in men than women (126.9 /ig/liter vs. 134.1 ^g/liter; p = 0.03). In age-adjusted analyses, IGF-I was not associated with height, total or central body fat, lean body mass, current smoking, physical activity, or commonly used medications. By contrast, in both men and women who reported any alcohol use, IGF-I levels were significantly higher compared with those in men and women who reported no alcohol use, and alcohol as a continuous variable showed a significant positive linear trend in men (p = 0.0007). The authors conclude that IGF-I varied significantly only with age, sex, and alcohol use. The minima) number of confounding variables, good reliability, and little intraindividual variation suggest that IGF-I should be suitable for epidemiologic research. Am J Epidemiol 1997;145:970-6. aged; alcohol drinking; insulin-like growth factor I; sex Insulin-like growth factor-I (IGF-I) is a growth hormone-dependent peptide that is structurally similar to insulin (1). It is abundant in the circulation and has been shown to be associated with protein (2), carbohydrate (3-5), and bone metabolism (6, 7). IGF-I may play a role in the pathophysiology of cancer (8), diabetes mellitus (9), cerebral ischemia (10), osteoporosis (11-13), and renal disease (14). Circulating levels of IGF-I are influenced by growth hormone, insulin, and endogenous sex hormones (15).
Insulin-like growth factor-I (IGF-I) is a growth hormone-dependent peptide that is structurally similar to insulin (1) . It is abundant in the circulation and has been shown to be associated with protein (2), carbohydrate (3) (4) (5) , and bone metabolism (6, 7) . IGF-I may play a role in the pathophysiology of cancer (8) , diabetes mellitus (9) , cerebral ischemia (10), osteoporosis (11) (12) (13) , and renal disease (14) . Circulating levels of IGF-I are influenced by growth hormone, insulin, and endogenous sex hormones (15) .
Although interest in IGF-I is increasing, only one small study has defined IGF-I concentrations in an adult population (16) and, to our knowledge, no previous large studies have described the epidemiology of IGF-I levels in older adults. In this paper, we describe individual, laboratory, diurnal, and seasonal variation in serum IGF-I levels, and the association of age, sex, body size and fat distribution, grip strength, alcohol and tobacco use, physical activity, and medications with IGF-I concentration in a community-based study of 420 men and 419 women aged 50 years and older.
MATERIALS AND METHODS
The subjects for this study were 419 consecutive women not currently using hormone replacement therapy and 420 consecutive men seen between 1992 and 1994. All were participants in the ongoing Rancho Bernardo Heart and Chronic Disease Study (17) , aged 50-97 years, white, community-dwelling and ambulatory. They were seen between 7:30 A.M. and 10:30 A.M. after a requested 12-hour fast. A standardized questionnaire was completed which queried current and past cigarette smoking, alcohol use during the past year, exercise history during the previous 2 weeks, and medication use. Weight was measured by trained observers using a balance-beam scale; subjects wore light clothing without shoes. Body mass index, calculated as weight (kg)/height (m) 2 , was used to estimate obesity. Height measured at the baseline visit approximately 20 years earlier was used as a proxy of "true" height to reduce the effect of height loss associated with age and osteoporosis. Waist and hip girth were measured in centimeters with a metal tape with the participant wearing single-thickness clothing and standing in an erect position with feet together. Waist was measured at both the bending point (point marked when participant naturally bends forward and measured after participant has realigned to an upright position) and the narrowest circumference. Hip circumference was measured at the iliac crest and at the largest circumference. Both waist and both hip measures were highly correlated. For consistency with our previously reported data, the bending point/iliac crest ratio was used for these analyses. Sagittal diameter, said to be an excellent anthropometric measure of visceral fat (18, 19) , was measured in centimeters using a Holtain Kahn Abdominal Caliper (Holtain Ltd., Crosswell, Crymych, Dyfed, UK). Sagittal diameter was measured, with the participant in the supine position with legs extended, as the vertical distance between the table and a mark midway between the left and right iliac crests. Bioelectric impedance was used to measure percent fat mass and percent lean body mass by assessing the voltage drop between two pairs of electrodes using an alternating current of 500 uA at a frequency of 50 kHz. Total body fat and regional body fat measurements, including truncal and leg fat, and lean body mass (kg) were measured using total body dual-energy x-ray absorptiometry (DEXA) (Hologic QDR-2000 X-Ray Bone Densitometer, Hologic, Inc., Waltham, Massachusetts), which uses a single beam scanning mode. Truncal fat boundaries included 1) superiorly, a line bisecting the glenoid fossas; 2) laterally, extending to above the iliac crests; and 3) inferiorly, oblique lines bisecting the femoral necks.
Leg fat was delineated by the area inferior to the oblique lines passing through the femoral necks. Waist/hip ratio, sagittal diameter, and the truncal fat/ leg fat ratio were used to estimate upper body obesity. (Note: central obesity and upper body obesity are used interchangeably in this paper). Waist circumference (at the bending point) was used as an integrated measure of obesity and fat distribution, based on studies showing that waist circumference is highly correlated with both total and visceral body fat (20, 21) .
Isometric grip strength was measured both in the nondominant and dominant hand using a dynamometer (Therapeutic Instruments Hand Dynamometer, Serial No. 06870823, Therapeutic Instruments Corp., Clifton, New Jersey). The dynamometer was placed in the hand with the participant's arm flexed 90° at the elbow and the forearm parallel to the floor. The participant was instructed to squeeze the hand maximally while simultaneously lowering the arm over three counts. Grip was released when the participant's arm was completely extended. One practice trial was allowed for each hand. The precision error for this instrument is 1.0 percent.
Serum for measurement of IGF-I was sent within 4 hours of venipuncture to a clinical endocrinology laboratory. Serum for repeat measurements was stored at -70°C. IGF-I was measured by immunoradiometric assay (IRMA) (22) . Total IGF-I was measured from serum using a highly specific immunoradiometric assay procedure which does not cross-react with other IGF components (22) . Samples were diluted and extracted with acid:ethanol (1:8) mixture to remove binding proteins. Samples were diluted in assay buffer to a final dilution of 1:198 prior to analysis by radioimmunoassay (RIA). The RIA utilizes recombinant DNA (99) pure IGF-I for standardization. The standard curve is linear from 10-600 ng/ml and the results of the analysis are calculated using a weighed logit-log data reduction. The assay sensitivity and intra-assay and inter-assay coefficients of variation were 0.80 ng/mL (27 pg/mL), 9.0 and 18.0 percent. Only one woman had an IGF-I level below the level of assay sensitivity, and she was excluded from all analyses. Outliers, defined as greater than or less than three standard deviations from the mean logged IGF-I level, were excluded (9 men and 5 women) from all analyses except those related to height alone.
Data were analyzed using SAS and SAS/STAT (SAS Institute Inc., Cary, North Carolina). Because IGF-I levels showed a slightly skewed distribution, analyses were performed using log-transformed data. To aid in the interpretation of the results, mean values are presented for untransformed data. However, all p values are based on logged data. Student's t tests were used for continuous variables and chi-square tests were used for categorical variables to test for statistical significance by baseline mean values between men and women. Seasonal and diurnal variation in IGF-I levels was assessed by comparing the age-adjusted mean IGF-I levels by month and time of venipuncture, respectively. Pearson's partial correlation coefficients were calculated to assess the strength of the association between IGF-I levels and measures of body composition and body fat distribution, life-style variables, and grip strength. Age-adjusted means of measures of body composition, body fat distribution, and grip strength by quartile of IGF-I were calculated using analysis of covariance. Analyses by quartiles were used to check for potential nonlinear associations; linear trends across quartiles were tested using linear contrasts in analysis of covariance models. Chi-square tests were used to test for statistical significance between frequencies of life-style variables and users of thyroid hormone, thiazides, or corticosteroids by quartile of IGF-I. All p values are two-tailed. No adjust-ment was made for multiple comparisons, and instead exact p values are shown. Table 1 shows the baseline characteristics of these 420 men and 419 women. Their average age was 74 and 77 years, respectively. Men had more central obesity, lean body mass, alcohol intake, and physical activity than women. Women had greater total body fat and were more likely to smoke than men. Men who were current smokers reported an average of 19.3 cigarettes per day (range 2-40 cigarettes per day) and an average duration of smoking of 47.9 years (range 7-73 years). Women who were current smokers consumed an average of 16.5 cigarettes per day (range 1-30 cigarettes per day) and had smoked an average of 44.4 years (20-60 years). Forty-eight percent of men and 37 percent of women reported daily alcohol intake; they consumed an average of 216.9 ± 127.9 ml and 161.3 ± 95.1 ml per week, respectively.
RESULTS

Within-person and laboratory reliability of IGF-I measurements
Duplicate samples from 10 randomly selected subjects were sent to the laboratory an average of 5.8 days apart to assess the reliability of the IGF-I measurement. There was a highly significant correlation between the two samples (r = 0.97; p -0.001), and the mean difference of 2.9 /xg/liter between the two samples was not significant (p = 0.47). In addition, 24 other subjects returned within 8 -54 days (mean = 42, SD = 14.8) for a repeat venipuncture and measurement of IGF-I level. Again, a highly significant correlation was seen between the two measurements (r = 0.94; p = 0.001), and the mean difference of -3.3 fxg/liter between the two samples was not significant (p = 0.27). IGF-I levels did not vary by season of sampling in either men or women (data not shown). Laboratory drift was assessed by comparing ageadjusted mean IGF-I levels by year of sampling. Although age-adjusted IGF-I levels were significantly lower in 1993 than 1992 (122.6 ptg/liter vs. 136.2 /xg/liter, p -0.02), the difference was observed only in women and the test for trend was not statistically significant for either sex. There was no difference in age-adjusted mean IGF-I levels by the hour of venipuncture, all of which were taken between 7:30 A.M. and 10:30 A.M. (data not shown).
Age and sex
Age-specific median IGF-I concentrations for men and women are shown in figure 1 . IGF-I decreased linearly with age for both men (p = 0.0001) and women (p = 0.002). For all age groups, except those aged 85 years and older, the median IGF-I level was lower for women than men. In an age-adjusted analysis, the sex difference was statistically significant (126.9 ± 2.2 /i,g/liter in women vs. 134.1 ± 2.2 /xg/liter in men, p = 0.03). The average decrease in IGF-I for each 10-year increase in age was 1.1 /ig/liter (p = 0.001) and 0.7 /xg/liter (p = 0.001), for men and women, respectively.
Body size
The age-adjusted mean IGF-I levels did not vary by percentile of baseline height for either men or women, even among the shortest subjects. Tables 2 and 3 show the age-adjusted correlation coefficients and means for measures of body composition by quartile of IGF-I for women and men, respectively. Only the correlation between IGF-I level and waist circumference reached statistical significance and only in women (r = 0.13; p = 0.05). Analysis by quartiles showed no evidence of a linear association between IGF-I concentration and baseline height or any measure of total body fat, abdominal obesity, or lean body mass in men or women. Analysis stratified by age at baseline (<60 years or ^60 years) did not alter these results (data not shown).
Life-style variables, medications, and muscle strength
IGF-I levels were higher in men and women who reported daily alcohol intake and in women who re- ported current smoking, but only alcohol intake in women was marginally significant. Age-adjusted mean IGF-I levels were significantly higher in men and women who reported any alcohol use in the past year than in those who reported no alcohol use (men, 137.7 ± 2.4 jig/liter vs. 118.8 ± 6.5 /i,g/liter, p = 0.0001; women, 128.3 ± 2.5 /xg/liter vs. 117.5 ± 4.7 /ig/liter, p = 0.04). A significant linear association between alcohol use and increasing serum IGF-I level was seen only in men (table 4). A comparison of men and women who exercised ^3 times a week with those who exercised <3 times a week showed no difference in IGF-I level. Similar results were obtained in analyses restricted to subjects aged <60 years. After exclusion of 14 men and one woman with conditions that affected grip strength (e.g., severe arthritis or stroke), mean grip strength in women and men was 18.1 ± 5.3 kg and 34.1 ± 8.6 kg, respectively, for the dominant hand and 16.6 ± 5.2 kg and 32.4 ± 8.4 kg, respectively, for the nondominant hand. There was no association between IGF-I level and grip strength in either the dominant or nondominant hand in either sex (data not shown). There was also no association of IGF-I with the most commonly used medications, thiazide diuretics, and thyroid and corticosteroid hormones (data not shown, all p's > 0.05).
DISCUSSION
In this older cohort, IGF-I levels decreased with age and were lower in women than men, a finding that is in agreement with that of previous studies (16, 23, 24) . The rate of decline in IGF-I with age in this population is less marked than has been previously reported in younger men and women (16) . These data suggest that the rate at which IGF-I decreases with age is reduced in the elderly and that gender differences in the rate of decline narrow. There was no significant seasonal or diurnal variation; the lack of diurnal variation has been reported previously (25) . In agreement with the only other community-based study (16) of which we are aware, most of the common potential covariates of life-style and medications were not associated with IGF-I levels. In Rancho Bernardo, IGF-I levels were associated only with age, sex, and alcohol use. This limited confounding should simplify the design, analysis, and interpretation of epidemiologic studies of IGF-I and disease.
The average levels of obesity and central obesity in men and women in this cohort of communitydwelling, ambulatory, elderly whites are similar to those reported in a national study (26) and a community-based study (27) , but IGF-I was not related to body mass index, total body fat, or lean body mass. These results differ from some, but not all, studies of the association of IGF-I with body composition. In some studies (16, (28) (29) (30) (31) , an inverse association has been reported between IGF-I levels and total body fat and lean body mass. These differences may reflect differences in age or body size. The studies that have found a significant association between IGF-I and total body fat and lean body mass included only younger men (30) or obese women (31) . There were very few obese subjects in Rancho Bernardo.
We also found no association between IGF-I and any measure of central obesity, including sagittal diameter, waist/hip ratio, and DEXA. These results are similar to those reported by Landin-Wilhelmsen et al. (26) , but differ from results reported by Marin et al. (28) , who found low serum IGF-I levels were associated with central obesity measured by sagittal diameter and computerized tomography. The Marin et al. study included only 27 men, whose mean age was 57 years (compared with 420 Rancho Bernardo men whose mean age was 74 years), and did not adjust for age, a strong confounding variable in our population. The differences are unlikely to be due to age differences, however, because waist/hip ratio in men and women aged <80 years has been shown to reliably measure body fat distribution compared with DEXA in our cohort (32) . Additional analyses restricted to subjects aged <60 years also showed no association of IGF-I with waist/hip ratio.
Although animal studies have suggested that alcohol decreases IGF-I levels (33), our data suggest an increase in IGF-I levels with increased alcohol use in both sexes. The mechanism for this association, which has not to our knowledge been reported previously, is most likely a reflection of a direct effect on the liver, a major source of IGF-I. The absent association between cigarette smoking and IGF-I is consistent with two previous studies (28, 34) , but differs from another study (26) , which reported a weak but statistically significant inverse association in an age-adjusted analysis in men between cigarette smoking and IGF-I levels. In agreement with our results, the authors did not find this association in women and were not able to demonstrate a dose-response relationship. It is possible that we were unable to find an association between smoking and IGF-I levels due to the small number of smokers in Rancho Bernardo.
It has been suggested (29) that the decrease in IGF-I levels with age is a result of a sedentary life-style. Our finding of a lack of association between IGF-I and physical activity or grip strength (which correlated with physical activity in the whole cohort (35)) does not support this hypothesis. Another epidemiologic study (26) also found no association between IGF-I and reported physical activity. Only maximal aerobic capacity (VO 2 max) and leisure-time activity have been reported to be independently associated with IGF-I levels in men (36) and women (37) . It is possible that these older adults were exercising below the threshold of benefit, but no association was seen in an analysis restricted to the men and women aged <60 years. If there is a true association, it is more likely that the failure to observe it reflects the poor sensitivity of reported exercise.
Two questions might be raised about the measurement of IGF-I for epidemiologic studies.
The first question is why not measure growth hormone directly. The IGF-I peptide is growth hormonedependent, such that individuals with growth hormone deficiency may have low IGF-I levels and their IGF-I concentrations increase after treatment with growth hormone (38, 39) . Nevertheless, there is not always a precise correlation between IGF-I and growth hormone levels, and some adults with growth hormone deficiency have normal levels of IGF-I (38, 40) . Neither growth hormone nor IGF-I levels can be used to exclude the diagnosis of adult onset growth hormone deficiency (where short stature within the normal height range is not helpful). Further, characterization of growth hormone levels, because of the pulsatile nature of growth hormone, requires a 24-hour collection, preferably after insulin challenge (40) . Thus, IGF-I, which has little diurnal variation and low pulsatility, becomes the most reliable surrogate for growth hormone status in the epidemiologic setting. Time will tell whether the decrement in IGF-I has a clinical significance which would call for replacement therapy in older adults.
The second question has to do with the value of IGF-I assays in the absence of concurrent measurement of IGF-binding protein, particularly IGF-binding protein 3 (IGFBP-3). Like IGF-I, IGFBP-3 levels increase as growth hormone levels increase (41, 42) . Because the IGFBP-3 levels appear to parallel IGF-I levels, measurement of IGF-I alone would be expected to be a good estimate of bioavailable IGF-I. Further work is needed in this area.
In summary, in this cohort of elderly men and women, IGF-I levels decrease with age and vary by sex and alcohol use, but are little affected by other commonly measured behavioral covariates. This finding, coupled with good reliability and little intraindividual variation, suggests that IGF-I can be used for epidemiologic studies of the role of both IGF-I and growth hormone in morbidity and mortality in the elderly.
